GlaxoSmithKline (GSK) Earns “Hold” Rating from Shore Capital

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by equities research analysts at Shore Capital in a research report issued to clients and investors on Thursday.

GSK has been the subject of several other reports. Goldman Sachs Group reissued a “buy” rating and set a GBX 1,900 ($26.64) price target on shares of GlaxoSmithKline in a report on Tuesday, October 17th. S&P Global set a GBX 1,500 ($21.03) price target on shares of GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, October 26th. HSBC reissued a “buy” rating and set a GBX 1,925 ($26.99) price target on shares of GlaxoSmithKline in a report on Wednesday, November 22nd. Morgan Stanley set a GBX 1,450 ($20.33) price target on shares of GlaxoSmithKline and gave the company a “sell” rating in a report on Monday, November 6th. Finally, Kepler Capital Markets cut their price target on shares of GlaxoSmithKline from GBX 1,520 ($21.31) to GBX 1,340 ($18.79) and set a “reduce” rating for the company in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (LON:GSK) traded down GBX 12.80 ($0.18) during mid-day trading on Thursday, reaching GBX 1,291 ($18.10). 11,680,000 shares of the company traded hands, compared to its average volume of 9,480,000. GlaxoSmithKline has a 12-month low of GBX 1,235.20 ($17.32) and a 12-month high of GBX 1,724.50 ($24.18). The company has a market cap of $64,010.00 and a P/E ratio of 4,164.52.

In other news, insider Sir Roy Anderson acquired 562 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was purchased at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total transaction of £262,000 ($367,358.38). In the last 90 days, insiders have purchased 581 shares of company stock valued at $743,284.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline (GSK) Earns “Hold” Rating from Shore Capital” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/11/glaxosmithkline-gsk-earns-hold-rating-from-shore-capital.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply